SG11202001377PA - Bisamide sarcomere activating compounds and uses thereof - Google Patents
Bisamide sarcomere activating compounds and uses thereofInfo
- Publication number
- SG11202001377PA SG11202001377PA SG11202001377PA SG11202001377PA SG11202001377PA SG 11202001377P A SG11202001377P A SG 11202001377PA SG 11202001377P A SG11202001377P A SG 11202001377PA SG 11202001377P A SG11202001377P A SG 11202001377PA SG 11202001377P A SG11202001377P A SG 11202001377PA
- Authority
- SG
- Singapore
- Prior art keywords
- bisamide
- activating compounds
- sarcomere
- sarcomere activating
- compounds
- Prior art date
Links
- 230000003213 activating effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- FTQWRYSLUYAIRQ-UHFFFAOYSA-N n-[(octadecanoylamino)methyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCNC(=O)CCCCCCCCCCCCCCCCC FTQWRYSLUYAIRQ-UHFFFAOYSA-N 0.000 title 1
- 210000002235 sarcomere Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762557846P | 2017-09-13 | 2017-09-13 | |
| PCT/US2018/050793 WO2019055590A1 (en) | 2017-09-13 | 2018-09-13 | SARCOMERIC BISAMIDE ACTIVATOR COMPOUNDS AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001377PA true SG11202001377PA (en) | 2020-03-30 |
Family
ID=63794635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001377PA SG11202001377PA (en) | 2017-09-13 | 2018-09-13 | Bisamide sarcomere activating compounds and uses thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US10723720B2 (es) |
| EP (1) | EP3681882A1 (es) |
| JP (1) | JP7308816B2 (es) |
| KR (1) | KR20200054237A (es) |
| CN (1) | CN111601798B (es) |
| AR (1) | AR112804A1 (es) |
| AU (1) | AU2018332887B2 (es) |
| BR (1) | BR112020004800A2 (es) |
| CA (1) | CA3075669A1 (es) |
| CL (1) | CL2020000610A1 (es) |
| CO (1) | CO2020002745A2 (es) |
| CR (1) | CR20200116A (es) |
| EA (1) | EA202090688A1 (es) |
| IL (1) | IL272573B2 (es) |
| JO (1) | JOP20200059A1 (es) |
| MA (1) | MA50173A (es) |
| MX (2) | MX2020002696A (es) |
| PH (1) | PH12020500446A1 (es) |
| SG (1) | SG11202001377PA (es) |
| TW (1) | TWI790281B (es) |
| UY (1) | UY37879A (es) |
| WO (1) | WO2019055590A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111601798B (zh) | 2017-09-13 | 2023-08-11 | 美国安进公司 | 双酰胺肌节活化化合物及其用途 |
| CA3099753A1 (en) * | 2018-05-29 | 2019-12-05 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| JP2022524609A (ja) * | 2019-03-12 | 2022-05-09 | アムジェン インコーポレイテッド | 心臓トロポニン活性化因子の多形及び共結晶 |
| EP3938042A1 (en) * | 2019-03-12 | 2022-01-19 | Amgen Inc. | Polymorphs of a cardiac troponin activator |
| CA3148216A1 (en) * | 2019-07-23 | 2021-01-28 | Bayer Aktiengesellschaft | Novel heteroaryl-triazole compounds as pesticides |
| CA3159167A1 (en) | 2019-12-04 | 2021-06-10 | Neil S. Cutshall | Masp-2 inhibitors and methods of use |
| BR112022010895A2 (pt) | 2019-12-04 | 2022-09-06 | Omeros Corp | Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan |
| EP4168393A1 (en) * | 2020-06-17 | 2023-04-26 | Merck Sharp & Dohme LLC | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors |
| AU2022239717A1 (en) | 2021-03-15 | 2023-11-02 | Maze Therapeutics, Inc. | Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
| WO2023122325A2 (en) * | 2021-12-23 | 2023-06-29 | Regents Of The University Of Michigan | Meta anilide compounds and methods for use of the same to treat diseases and disorders |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0662529B2 (ja) | 1984-07-13 | 1994-08-17 | 三共株式会社 | アミノ酸誘導体 |
| US5952307A (en) | 1994-01-21 | 1999-09-14 | Georgia Tech Research Corp. | Basic α-aminoalkylphosphonate derivatives |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| GB9708119D0 (en) | 1997-04-22 | 1997-06-11 | Glaxo Group Ltd | Chemical compounds |
| AU1082901A (en) | 1999-10-18 | 2001-04-30 | National Jewish Medical And Research Center | Method for modulation of cell phenotype |
| AU2001231202A1 (en) | 2000-01-28 | 2001-08-07 | Akkadix Corporation | Methods for killing nematodes and nematode eggs using 4-phenoxy-6-aminopyrimidine derivatives |
| EP1125925A1 (en) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
| US6495337B1 (en) | 2000-03-29 | 2002-12-17 | Cytokinetics, Inc. | High throughput sarcomeric assay |
| US20030078376A1 (en) | 2000-11-07 | 2003-04-24 | Board Of Regents, The University Of Texas System | Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| WO2003059265A2 (en) | 2001-12-21 | 2003-07-24 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| AU2002367023A1 (en) | 2001-12-21 | 2003-07-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| EP2397462A3 (en) | 2003-01-14 | 2012-04-04 | Cytokinetics, Inc. | Compounds, compositions and methods of treatment for heart failure |
| JP4969238B2 (ja) | 2003-03-27 | 2012-07-04 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
| WO2004094610A2 (en) | 2003-04-21 | 2004-11-04 | Baylor College Of Medicine | Wnt as a factor for cardiac myogenesis |
| US7541466B2 (en) | 2003-12-23 | 2009-06-02 | Genzyme Corporation | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases |
| JP2005298628A (ja) | 2004-04-09 | 2005-10-27 | Sumitomo Chemical Co Ltd | オレフィン重合触媒成分及びオレフィン重合体の製造方法 |
| EP2862859B1 (en) | 2004-06-17 | 2018-07-25 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US20070208000A1 (en) | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| AR058347A1 (es) | 2005-12-15 | 2008-01-30 | Cytokinetics Inc | Entidades quimias composiciones y metodos |
| US7718657B2 (en) | 2005-12-16 | 2010-05-18 | Cytokinetics, Inc. | Certain indanyl urea modulators of the cardiac sarcomere |
| US7989455B2 (en) | 2005-12-19 | 2011-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2007089805A2 (en) | 2006-01-31 | 2007-08-09 | The General Hospital Corporation | Anti-hypertrophic effects and inotropic effects of picot |
| US20080227823A1 (en) | 2007-03-12 | 2008-09-18 | Hassan Pajouhesh | Amide derivatives as calcium channel blockers |
| GB0708818D0 (en) | 2007-05-08 | 2007-06-13 | Portela & Ca Sa | Compounds |
| US20090192168A1 (en) | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| JP2014534206A (ja) | 2011-10-17 | 2014-12-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｃ型肝炎ウイルス阻害剤 |
| WO2013106646A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| EP3608317A1 (en) | 2012-01-12 | 2020-02-12 | Yale University | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| JP6634368B2 (ja) | 2013-03-14 | 2020-01-22 | アムジエン・インコーポレーテツド | 複素環式化合物及びそれらの使用 |
| WO2015103527A1 (en) | 2014-01-06 | 2015-07-09 | The Scripps Research Institute | Modulators of rev-erb |
| WO2015142001A2 (ko) | 2014-03-21 | 2015-09-24 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
| MX2021010778A (es) | 2015-01-22 | 2022-08-11 | Myokardia Inc | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd). |
| MX2017011919A (es) | 2015-03-18 | 2018-05-22 | Arvinas Inc | Compuestos y metodos para la degradacion mejorada de proteinas especificas. |
| US10829440B2 (en) | 2015-06-12 | 2020-11-10 | Brown University | Antibacterial compounds and methods of making and using same |
| KR101766731B1 (ko) | 2015-06-23 | 2017-08-10 | 충남대학교산학협력단 | 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물 |
| AU2016282985B2 (en) | 2015-06-26 | 2021-07-29 | Amgen Inc. | Combination therapy of cardiac myosin activator and sinus node if current inhibitor |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| KR20160108281A (ko) | 2016-09-06 | 2016-09-19 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
| SI3645518T1 (sl) | 2017-06-30 | 2021-11-30 | Amgen Inc. | Sinteza omekamtiv mekarbila |
| CN111601798B (zh) | 2017-09-13 | 2023-08-11 | 美国安进公司 | 双酰胺肌节活化化合物及其用途 |
| LT3594199T (lt) | 2018-07-09 | 2020-11-10 | F.I.S.- Fabbrica Italiana Sintetici S.P.A. | Kristalinis 2-fluor-3-nitroluenas ir jo paruošimo būdas |
| AU2019321573A1 (en) | 2018-08-17 | 2021-03-04 | Amgen Inc. | Salts and crystal forms of omecamtiv mecarbil |
| WO2020131574A1 (en) | 2018-12-18 | 2020-06-25 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| EP3938042A1 (en) | 2019-03-12 | 2022-01-19 | Amgen Inc. | Polymorphs of a cardiac troponin activator |
| JP2022524609A (ja) | 2019-03-12 | 2022-05-09 | アムジェン インコーポレイテッド | 心臓トロポニン活性化因子の多形及び共結晶 |
-
2018
- 2018-09-13 CN CN201880072907.5A patent/CN111601798B/zh active Active
- 2018-09-13 WO PCT/US2018/050793 patent/WO2019055590A1/en active Application Filing
- 2018-09-13 AU AU2018332887A patent/AU2018332887B2/en active Active
- 2018-09-13 CR CR20200116A patent/CR20200116A/es unknown
- 2018-09-13 KR KR1020207010115A patent/KR20200054237A/ko not_active Application Discontinuation
- 2018-09-13 TW TW107132171A patent/TWI790281B/zh active
- 2018-09-13 MX MX2020002696A patent/MX2020002696A/es unknown
- 2018-09-13 EA EA202090688A patent/EA202090688A1/ru unknown
- 2018-09-13 CA CA3075669A patent/CA3075669A1/en active Pending
- 2018-09-13 IL IL272573A patent/IL272573B2/en unknown
- 2018-09-13 MA MA050173A patent/MA50173A/fr unknown
- 2018-09-13 JP JP2020514579A patent/JP7308816B2/ja active Active
- 2018-09-13 US US16/129,862 patent/US10723720B2/en active Active
- 2018-09-13 SG SG11202001377PA patent/SG11202001377PA/en unknown
- 2018-09-13 JO JOP/2020/0059A patent/JOP20200059A1/ar unknown
- 2018-09-13 EP EP18783202.7A patent/EP3681882A1/en active Pending
- 2018-09-13 AR ARP180102603A patent/AR112804A1/es unknown
- 2018-09-13 BR BR112020004800-3A patent/BR112020004800A2/pt unknown
- 2018-09-13 UY UY0001037879A patent/UY37879A/es unknown
-
2020
- 2020-03-05 PH PH12020500446A patent/PH12020500446A1/en unknown
- 2020-03-10 CL CL2020000610A patent/CL2020000610A1/es unknown
- 2020-03-10 MX MX2022014864A patent/MX2022014864A/es unknown
- 2020-03-10 CO CONC2020/0002745A patent/CO2020002745A2/es unknown
- 2020-03-27 US US16/833,321 patent/US11254658B2/en active Active
- 2020-03-27 US US16/833,336 patent/US10899746B2/en active Active
- 2020-10-12 US US17/068,518 patent/US11299479B1/en active Active
-
2022
- 2022-02-15 US US17/672,594 patent/US11780826B2/en active Active
-
2023
- 2023-08-17 US US18/451,757 patent/US20240158372A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272573A (en) | Sarcomere activating bisamide compounds and their uses | |
| IL273236A (en) | Pyrazolopyrimidine compounds and their uses | |
| GB201708652D0 (en) | Novel compounds and uses | |
| GB201714745D0 (en) | New compounds and uses | |
| GB201714740D0 (en) | New compounds and uses | |
| HK1257539A1 (zh) | 新的化合物及其用途 | |
| IL292488B1 (en) | Pyridineamine-pyridone and pyrimidineamine-pyridone compounds | |
| GB201714734D0 (en) | New compounds and uses | |
| GB201616439D0 (en) | Compounds and uses | |
| IL267626B1 (en) | Teraaryl compounds and their uses | |
| GB201714736D0 (en) | New compounds and uses | |
| IL267937A (en) | Amide compounds and their use | |
| IL265531A (en) | N 3 -cyclically substituted thienouraciles and use thereof | |
| SG11202002224XA (en) | Composition and uses thereof | |
| SG11201912432VA (en) | Emm-23 materials and processes and uses thereof | |
| IL275211A (en) | Fast and flexible segment chains - division | |
| IL292482B2 (en) | Azaindolylpyridone and diazaindolylpyridone compounds | |
| GB201712110D0 (en) | New compounds and uses | |
| GB201700404D0 (en) | Compounds and composistions | |
| SG11202005282VA (en) | Emm-31 materials and processes and uses thereof | |
| GB201614224D0 (en) | Compounds and uses thereof | |
| GB201720092D0 (en) | New Compounds and uses | |
| GB201719327D0 (en) | New compounds and uses | |
| GB201719233D0 (en) | New compounds and uses | |
| GB201714743D0 (en) | New compounds and uses |